| Literature DB >> 24367533 |
Tomohiro Kotaki1, Siti Qamariyah Khairunisa2, Septhia Dwi Sukartiningrum2, M Vitanata Arfijanto3, Takako Utsumi1, Irine Normalina2, Retno Handajani3, Prihartini Widiyanti2, Musofa Rusli3, Retno Pudji Rahayu2, Maria Inge Lusida3, Yoshitake Hayashi4, Masanori Kameoka5.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) cause serious health problems and have an impact on the Indonesian economy. In addition, the rapid epidemic growth of HIV is continuing in Indonesia. Commercial sex plays a significant role in the spread of HIV; therefore, in order to reveal the current HIV prevalence rate among commercial sex workers (CSWs), we conducted an epidemiological study on HIV infection among CSWs residing in Surabaya, the capital of East Java province of Indonesia with large communities of CSWs. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2013 PMID: 24367533 PMCID: PMC3867361 DOI: 10.1371/journal.pone.0082645
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic information of HIV-positive and -negative CSWs enrolled in this study.
| HIV-positive | HIV-negative | |||||||
| Total (%) | Urban area 1 (%) | Urban area 2 (%) | Rural area (%) | Total (%) | Urban area 1 (%) | Urban area 2 (%) | Rural area (%) | |
| Sample number | 22 | 0 | 12 | 10 | 178 | 13 | 112 | 53 |
| Gender | ||||||||
| Male | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (1.7) | 3 (23.1) | 0 (0.0) | 0 (0.0) |
| Female | 22 (100.0) | 0 (0.0) | 12 (100.0) | 10 (100.0) | 175 (98.3) | 10 (76.9) | 112 (100.0) | 53 (100.0) |
| Age (years old) | ||||||||
| <20 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (3.4) | 1 (7.7) | 3 (2.7) | 2 (3.8) |
| 20–29 | 13 (59.1) | 0 (0.0) | 6 (50.0) | 7 (70.0) | 55 (30.9) | 4 (30.8) | 27 (24.1) | 24 (45.3) |
| 30–39 | 4 (18.2) | 0 (0.0) | 2 (16.7) | 2 (20.0) | 78 (43.8) | 5 (38.5) | 57 (50.9) | 16 (30.2) |
| >40 | 4 (18.2) | 0 (0.0) | 4 (33.3) | 0 (0.0) | 32 (18.0) | 3 (23.1) | 24 (21.4) | 5 (9.4) |
| No answer | 1 (4.5) | 0 (0.0) | 0 (0.0) | 1 (10.0) | 7 (3.9) | 0 (0.0) | 1 (0.9) | 6 (11.3) |
| Latest educational background | ||||||||
| Elementary school | 10 (45.5) | 0 (0.0) | 8 (66.7) | 2 (20.0) | 78 (43.8) | 0 (0.0) | 63 (56.3) | 15 (28.3) |
| Junior high school | 7 (31.8) | 0 (0.0) | 2 (16.7) | 5 (50.0) | 47 (26.4) | 2 (15.4) | 25 (22.3) | 20 (37.7) |
| High school | 1 (4.5) | 0 (0.0) | 0 (0.0) | 1 (10.0) | 30 (16.9) | 9 (69.2) | 13 (11.6) | 8 (15.1) |
| University | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (1.7) | 2 (15.4) | 1 (0.9) | 0 (0.0) |
| No answer | 4 (18.2) | 0 (0.0) | 2 (16.7) | 2 (20.0) | 20 (11.2) | 0 (0.0) | 10 (8.9) | 10 (18.9) |
| Duration of commercial sex work | ||||||||
| <3 months | 1 (4.5) | 0 (0.0) | 0 (0.0) | 1 (10.0) | 20 (11.2) | 0 (0.0) | 11 (9.8) | 9 (17.0) |
| 3–12 months | 6 (27.3) | 0 (0.0) | 2 (16.7) | 4 (40.0) | 31 (17.4) | 0 (0.0) | 17 (15.2) | 14 (26.4) |
| 1–3 years | 12 (54.5) | 0 (0.0) | 7 (58.3) | 5 (50.0) | 60 (33.7) | 1 (7.7) | 43 (38.4) | 16 (30.2) |
| >3 years | 3 (13.6) | 0 (0.0) | 3 (25.0) | 0 (0.0) | 55 (30.9) | 12 (92.3) | 36 (32.1) | 7 (13.2) |
| No answer | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 12 (6.7) | 0 (0.0) | 5 (4.5) | 7 (13.2) |
| Number of clients per week | ||||||||
| 1–3 | 7 (31.8) | 0 (0.0) | 3 (25.0) | 4 (40.0) | 32 (18.0) | 7 (53.8) | 20 (17.9) | 5 (9.4) |
| 4–6 | 6 (27.3) | 0 (0.0) | 6 (50.0) | 0 (0.0) | 60 (33.7) | 3 (23.1) | 48 (42.9) | 9 (17.0) |
| >7 | 7 (31.8) | 0 (0.0) | 3 (25.0) | 4 (40.0) | 50 (28.1) | 0 (0.0) | 30 (26.8) | 20 (37.7) |
| no answer | 2 (9.1) | 0 (0.0) | 0 (0.0) | 2 (20.0) | 36 (20.2) | 3 (23.1) | 14 (12.5) | 19 (35.8) |
| Awareness of sexually transmitted diseases | ||||||||
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 10 (5.6) | 10 (76.9) | 0 (0.0) | 0 (0.0) |
| No | 19 (86.4) | 0 (0.0) | 12 (100.0) | 7 (70.0) | 144 (80.9) | 0 (0.0) | 109 (97.3) | 35 (66.0) |
| No answer | 3 (13.6) | 0 (0.0) | 0 (0.0) | 3 (30.0) | 24 (13.5) | 3 (23.1) | 3 (2.7) | 18 (34.0) |
| Condom use | ||||||||
| Yes | 3 (13.6) | 0 (0.0) | 0 (0.0) | 3 (30.0) | 10 (5.6) | 0 (0.0) | 0 (0.0) | 10 (18.9) |
| No | 19 (86.4) | 0 (0.0) | 12 (100.0) | 7 (70.0) | 160 (89.9) | 13 (100.0) | 111 (99.1) | 36 (67.9) |
| No answer | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 8 (4.5) | 0 (0.0) | 1 (0.9) | 7 (13.2) |
| Drug use | ||||||||
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 14 (7.9) | 11 (84.6) | 3 (2.7) | 0 (0.0) |
| No | 22 (100.0) | 0 (0.0) | 12 (100.0) | 10 (100.0) | 159 (89.3) | 2 (15.4) | 108 (96.4) | 49 (92.5) |
| No answer | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (2.8) | 0 (0.0) | 1 (0.9) | 4 (7.5) |
*Plasma sample was tested for anti-HIV antibodies using a rapid diagnostic kit, and was then tested using 2 additional diagnostic kits to confirm the diagnosis of HIV infection.
**The proportion (%) of number of individuals in a question item is shown in parentheses.
Viral subtype and CRF detected in the blood samples of HIV-1-positive CSWs.*
| HIV-1 gene | ||
| sample ID |
|
|
| SM2 | CRF01_AE | CRF01_AE |
| SM11 | CRF01_AE | CRF01_AE |
| SM15 | CRF01_AE | nd |
| SM18 | CRF01_AE | CRF01_AE |
| SM26 | CRF01_AE | CRF01_AE |
| SM35 | CRF01_AE | CRF01_AE |
| SM44 | CRF01_AE | CRF01_AE |
| SM51 | CRF01_AE | CRF01_AE |
| SM56 | CRF01_AE | CRF01_AE |
| SM65 | CRF01_AE | CRF01_AE |
| PJ22 | CRF01_AE | CRF01_AE |
| PJ28 | CRF01_AE | CRF01_AE |
| PJ37 | CRF01_AE | CRF01_AE |
| PJ39 | CRF01_AE | CRF01_AE |
| PJ68 | CRF01_AE | CRF01_AE |
| PJ81 | CRF01_AE | nd |
| PJ90 | CRF01_AE | CRF01_AE |
| PJ105 | CRF01_AE | CRF01_AE |
| PJ109 | CRF01_AE | CRF01_AE |
| PJ117 | CRF01_AE | CRF01_AE |
| PJ119 | CRF01_AE | CRF01_AE |
| PJ121 | CRF01_AE | Subtype A1 |
*HIV-1 pol and env genes were amplified and subjected to sequencing analysis.
Viral subtyping was carried out using the Recombinant Identification Program (RIP).
**HIV-1 env gene failed to be amplified; therefore, viral subtyping was not carried out.
Figure 1Phylogenetic relationship of HIV-1 pol and env gene sequences.
Phylogenetic trees were generated for newly sequenced HIV-1 pol (A) and env (B) genes together with the corresponding viral gene of reference HIV-1 strains representing subtype A1 (A1), subtype A2 (A2), subtype B (B), subtype C (C), subtype D (D), CRF01_AE (AE), CRF02_AG (AG), CRF15_01B (15_01B), CRF33_01B (33_01B) and CRF34_01B (34_01B) (shown with a gray background). Bootstrap values are shown when the values are >50. Scale bar represents 0.01 (A) or 0.02 nucleotide substitutions per site (B). The nucleotide sequences of pol and env genes determined in this study have been deposited in the GenBank database under accession numbers KF147334-KF147375.
Sero-prevalence of HBsAg, anti-HBc Ab, anti-HCV Ab and anti-GBV-C Ab among CSWs residing in Surabaya.*
| All participants | HIV-positive | HIV-negative | ||||||||||
| Total (n = 200) | Urban area 1 (n = 13) | Urban area 2 (n = 124) | Rural area (n = 63) | Total (n = 22) | Urban area 1 (n = 0) | Urban area 2 (n = 12) | Rural area (n = 10) | Total (n = 178) | Urban area 1 (n = 13) | Urban area 2 (n = 112) | Rural area (n = 53) | |
| HBsAg -positive | 8 (4.0) | 0 (0.0) | 5 (4.0) | 3 (4.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 8 (4.5) | 0 (0.0) | 5 (4.5) | 3 (5.7) |
| Anti-HBc Ab-positive | 128 (64) | 7 (53.8) | 77 (62.1) | 44 (70.0) | 17 (77.2) | 0 (0.0) | 9 (75.0) | 8 (80.0) | 111 (62.4) | 7 (53.8) | 68 (60.7) | 36 (68.0) |
| Anti-HCV Ab-positive | 1 (0.5) | 0 (0.0) | 1 (0.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Anti-GBV-C Ab-positive | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
*Plasma sample was tested for HBsAg, anti-HBc Ab, anti-HCV Ab and anti-GBV-C Ab using commertially available diagnostic kits.
**Plasma sample was tested for anti-HIV antibodies using a rapid diagnostic kit, and was then tested using 2 additional diagnostic kits to confirm the diagnosis of HIV infection.
***The sero-prevalence rate (%) among a group of CSWs indicated is shown in parentheses.